A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs GRF 6021 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Alkahest
- 04 Dec 2018 According to a Alkahest media release, first patient has been dosed in this trial. This trial is being conducted with support from The Michael J. Fox Foundation.
- 20 Nov 2018 Status changed from not yet recruiting to recruiting.
- 30 Oct 2018 New trial record